MSK
Search
- Page Path
- HOME > Search
- Microbiome therapeutic PMC72 through reverse translational research in gout
- Mohammed Solayman Hossain, Hoonhee Seo, Kyung-Ann Lee, Asad ul-Haq, Sukyung Kim, Sujin Jo, Md Abdur Rahim, Hanieh Tajdozian, Fatemeh Ghorbanian, Youjin Yoon, Indrajeet Barman, Md Sarower Hossen Shuvo, Hyun-Sook Kim, Ho-Yeon Song
- J. Microbiol. 2025;63(5):e2501002. Published online May 27, 2025
- DOI: https://doi.org/10.71150/jm.2501002
- 194 View
- 12 Download
-
Abstract
PDF
Supplementary Material -
Gout is an inflammatory arthritis resulting from the deposition of monosodium urate crystals. Urate-lowering therapies for gout have limitations, including side effects and limited efficacy, highlighting the need for novel therapeutic approaches to improve patient outcomes. In this context, our research team conducted a microbiome analysis of fecal samples from healthy individuals and gout patients, identifying Bifidobacterium as a key biomarker. Subsequently, we isolated and identified this strain, B. longum PMC72, and demonstrated its efficacy in a gout mouse model. In potassium oxonate (PO)-induced hyperuricemia mice, PMC72 significantly alleviated nausea, gait disturbances, ankle inflammation, and improved renal health. These effects were associated with marked reductions in oxidative stress markers, including serum uric acid, blood urea nitrogen, hepatic xanthine oxidase, and malondialdehyde (MDA) levels in serum, liver, and joint samples, as well as the downregulation of inflammation and uric acid transport-related gene expression in kidney samples. These benefits were comparable to those treated with Febuxostat, a standard urate-lowering therapy for gout. Furthermore, gut microbiome analysis revealed that PMC72 restored dysbiosis induced by hyperuricemia, contrasting with the reduced microbial diversity observed with febuxostat alone, and showed a complete recovery to eubiosis when combined with Febuxostat. These findings position PMC72 as a promising microbial therapeutic candidate for gout management, demonstrating significant development potential and serving as a benchmark for reverse translational microbiome-based therapeutic research.
- Activity of Lactobacillus crispatus isolated from vaginal microbiota against Mycobacterium tuberculosis
- Youngkyoung Lee , Hoonhee Seo , Sukyung Kim Abdur Rahim , Youjin Yoon , Jehee Jung , Saebim Lee , Chang Beom Ryu , Ho-Yeon Song
- J. Microbiol. 2021;59(11):1019-1030. Published online November 1, 2021
- DOI: https://doi.org/10.1007/s12275-021-1332-0
- 88 View
- 0 Download
- 8 Web of Science
- 9 Crossref
-
Abstract
-
Tuberculosis, an infectious disease, is caused by Mycobacterium
tuberculosis. It remains a significant public health issue
around the globe, causing about 1.8 million deaths every year.
Drug-resistant M. tuberculosis, including multi-drug-resistant
(MDR), extremely-drug-resistant (XDR), and totally drugresistant
(TDR) M. tuberculosis, continues to be a threat to
public health. In the case of antibiotic-resistant tuberculosis,
the treatment effect of conventional antibiotics is low. Side
effects caused by high doses over a long period are causing
severe problems. To overcome these problems, there is an urgent
need to develop a new anti-tuberculosis drug that is different
from the existing compound-based antibiotics. Probiotics
are defined as live microorganisms conferring health
benefits. They can be potential therapeutic agents in this context
as the effectiveness of probiotics against different infectious
diseases has been well established. Here, we report that
Lactobacillus crispatus PMC201 shows a promising effect on
tuberculosis isolated from vaginal fluids of healthy Korean
women. Lactobacillus crispatus PMC201 reduced M. tuberculosis
H37Rv under co-culture conditions in broth and reduced
M. tuberculosis H37Rv and XDR M. tuberculosis in macrophages.
Lactobacillus crispatus PMC201 was not toxic to a
guinea pig model and did not induce dysbiosis in a human
intestinal microbial ecosystem simulator. Taken together, these
results
indicate that L. crispatus PMC201 can be a promising alternative drug candidate in the current tuberculosis drug regime. Further study is warranted to assess the in vivo efficacy and confirm the mode of action of L. crispatus PMC201. -
Citations
Citations to this article as recorded by
- Insights into Autophagy in Microbiome Therapeutic Approaches for Drug-Resistant Tuberculosis
Md Abdur Rahim, Hoonhee Seo, Indrajeet Barman, Mohammed Solayman Hossain, Md Sarower Hossen Shuvo, Ho-Yeon Song
Cells.2025; 14(7): 540. CrossRef - The potential role of probiotics and their bioactive compounds in the management of pulmonary tuberculosis
Hamed Memariani, Mojtaba Memariani, Seyed Ebrahim Eskandari, Abdolmajid Ghasemian, Ali Nour Neamatollahi
Journal of Infection and Public Health.2025; : 102840. CrossRef - Exploring the potential of Lactocaseibacillus rhamnosus PMC203 in inducing autophagy to reduce the burden of Mycobacterium tuberculosis
Md Abdur Rahim, Hoonhee Seo, Sukyung Kim, Indrajeet Barman, Fatemeh Ghorbanian, Mohammed Solayman Hossain, Md Sarower Hossen Shuvo, Saebim Lee, Ho-Yeon Song
Medical Microbiology and Immunology.2024;[Epub] CrossRef - Efficacy of lyophilized Lactobacillus sakei as a potential candidate for preventing carbapenem-resistant Klebsiella infection
Hanieh Tajdozian, Hoonhee Seo, Yoonkyoung Jeong, Fatemeh Ghorbanian, Chae-eun Park, Faezeh Sarafraz, Md Abdur Rahim, Youngkyoung Lee, Sukyung Kim, Saebim Lee, Jung-Hyun Ju, Chul-Ho Kim, Ho-Yeon Song
Annals of Microbiology.2024;[Epub] CrossRef - Identification of Probiotic Strains with Anti-Tuberculosis Activity and Their Characterization as Potential Therapeutic Agents
Mohammed Solayman Hossain, Hoonhee Seo, Md Abdur Rahim, Md Sarower Hossen Shuvo, Indrajeet Barman, Hokyoung Kim, Jinhyeon An, Sukyung Kim, Ho-Yeon Song
Journal of Bacteriology and Virology.2024; 54(4): 325. CrossRef - The gut and lung microbiota in pulmonary tuberculosis: susceptibility, function, and new insights into treatment
Qiqi Zhuo, Xianyi Zhang, Kehong Zhang, Chan Chen, Zhen Huang, Yuzhong Xu
Expert Review of Anti-infective Therapy.2023; 21(12): 1355. CrossRef - Host microbiome in tuberculosis: disease, treatment, and immunity perspectives
Archana Pant, Bhabatosh Das, Gopalakrishnan Aneeshkumar Arimbasseri
Frontiers in Microbiology.2023;[Epub] CrossRef - Antibiotic Resistance to Mycobacterium tuberculosis and Potential Use of Natural and Biological Products as Alternative Anti-Mycobacterial Agents
Roberto Arrigoni, Andrea Ballini, Skender Topi, Lucrezia Bottalico, Emilio Jirillo, Luigi Santacroce
Antibiotics.2022; 11(10): 1431. CrossRef -
In Vivo Efficacy of Bacillus velezensis Isolated from Korean Gochang Bokbunja Vinegar against Carbapenem-Resistant Klebsiella pneumoniae Infections
Fatemeh Ghorbanian, Hoonhee Seo, Hanieh Tajdozian, Youngkyoung Lee, MD Abdur Rahim, Sukyung Kim, Il-Yun Jung, Saebim Lee, Ho-Yeon Song
Polish Journal of Microbiology.2022; 71(4): 553. CrossRef
- Insights into Autophagy in Microbiome Therapeutic Approaches for Drug-Resistant Tuberculosis
First
Prev
TOP
